{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal to', 'X ULN.', '10. Adequate renal function within 28 days prior to C1D1 (estimated creatinine clearance', '[CrCl] of>20 mL/min, calculated using the formula of Cockroft and Gault):', '(140-Age) X Mass (kg)(72 X creatinine mg/dL)', 'Multiply by 0.85 if the patient is female, or if CrCl is >20 mL/min as measured by', '24-hour urine collection.', '11. Adequate hematopoietic function within 7 days prior to C1D1: total white blood cell', '(WBC) count 1500/mm\u00b3, absolute neutrophil count 1000/mm\u00b3, hemoglobin >8.5 g/dL', 'and platelet count >75,000/mm\u00b3 (patients for whom < 50% of bone marrow nucleated', 'cells are plasma cells) or >50,000/mm\u00b3 (patients for whom >50% of bone marrow', 'nucleated cells are plasma cells).', 'a. Patients receiving hematopoietic growth factor support, including erythropoietin,', 'darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte', 'macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (eg,', 'eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between', 'growth factor support and the Screening assessments, but they may receive growth', 'factor support during the study.', 'b. Patients must have:', '- At least a 2-week interval from the last red blood cell (RBC) transfusion prior to', 'the Screening hemoglobin assessment, and', '- At least a 1-week interval from the last platelet transfusion prior to the Screening', 'platelet assessment.', 'However, patients may receive RBC and/or platelet transfusions as clinically indicated', 'per institutional guidelines during the study.', '12. Female patients of childbearing potential must have a negative serum pregnancy test at', 'Screening. Female patients of childbearing potential and fertile male patients who are', 'sexually active with a female of childbearing potential must use highly effective methods', 'of contraception throughout the study and for 3 months following the last dose of study', 'treatment. Highly effective methods of contraception are listed in Section 10.8.1.', '7.3.', 'Exclusion Criteria', 'Patients meeting any of the following exclusion criteria are not eligible to enroll in this study:', '1. Prior exposure to a SINE compound, including selinexor.', '2. Prior malignancy that required treatment or has shown evidence of recurrence (except for', 'non-melanoma skin cancer or adequately treated cervical carcinoma in situ) during the', '5 years prior to randomization. Cancer treated with curative intent for >5 years previously', 'and without evidence of recurrence will be allowed.', 'Confidential', 'Page 52', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '3. Has any concurrent medical condition or disease (eg, uncontrolled active hypertension,', 'uncontrolled active diabetes, active systemic infection, etc.) that is likely to interfere with', 'study procedures.', '4. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals', 'within 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled', 'infection within 1 week prior to C1D1 are acceptable.', '5. Active plasma cell leukemia.', '6. Documented systemic light chain amyloidosis.', '7. MM involving the central nervous system.', '8. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin', 'changes (POEMS) syndrome.', '9. Spinal cord compression.', '10. Greater than Grade 2 peripheral neuropathy or Grade >2 peripheral neuropathy with pain', 'at baseline, regardless of whether or not the patient is currently receiving medication.', '11. Known intolerance, hypersensitivity, or contraindication to glucocorticoids.', '12. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy (including', 'investigational therapies) <2 weeks prior to C1D1. Localized radiation to a single site at', 'least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1 are', 'permitted. Patients on long-term glucocorticoids during Screening do not require a', 'washout period but must be able to tolerate the specified dexamethasone dose in this', 'study.', '13. Prior autologous stem cell transplantation <1 month or allogeneic stem cell', 'transplantation <4 months prior to C1D1.', '14. Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.', '15. Pregnant or breastfeeding females.', '16. BSA <1.4 m\u00b2 at baseline, calculated by the Dubois (Dubois 1916) or Mosteller (Mosteller', '1987) method.', '17. Life expectancy of <4 months.', '18. Major surgery within 4 weeks prior to C1D1.', '19. Active, unstable cardiovascular function:', 'a. Symptomatic ischemia, or', 'b. Uncontrolled clinically significant conduction abnormalities (eg, patients with', 'ventricular tachycardia on anti-arrhythmics are excluded; patients with first-degree', 'atrioventricular block or asymptomatic left anterior fascicular block/right bundle', 'branch block will not be excluded), or', 'c.', 'Congestive heart failure of New York Heart Association Class >3 or known left', 'ventricular ejection fraction <40%, or', 'd. Myocardial infarction within 3 months prior to C1D1.', 'Confidential', 'Page 53', 'Version 4.0']\n\n###\n\n", "completion": "END"}